Key Takeaways
BRAIN Biotech AG Elevator Pitch Presentation
In this seat11a Elevator Pitch, Michael Schneiders, CFO of BRAIN Biotech AG, presents the company’s business model, biotechnology platform, and long-term growth strategy.
Biotechnology Platform for Sustainable Industrial Solutions
BRAIN Biotech develops enzyme products, microorganisms, and biological solutions that help customers replace conventional industrial processes with more sustainable biotechnology-based alternatives. The company serves customers across food, beverage, life sciences, proteins, dairy, and other specialty industrial markets through its integrated biotechnology platform.
Two Complementary Business Pillars
The business is built around two complementary pillars. The BRAINBiocatalysts division develops and produces specialty enzymes and microbial solutions while providing contract research and manufacturing services. The BRAINBioIncubator focuses on breakthrough innovation projects, strategic participations, and pharmaceutical royalty opportunities that have the potential to create significant additional value over time.
Balanced Business Model and Financial Performance
Management explains how this combination creates a balanced business model, generating profitable operating revenues while maintaining exposure to higher-value innovation projects. During FY 2024/25, BRAIN Biotech generated approximately €45.4 million in annual revenue, €4.4 million adjusted EBITDA, and approximately €4.2 million in recurring revenues, providing a solid financial foundation for future growth.
Medium-Term Growth Targets and Expansion Strategy
Looking ahead, the company has set ambitious medium-term objectives presented at its 2024 Capital Markets Day. Within its BRAINBiocatalysts division, management targets €100 million in revenue together with an adjusted EBITDA margin of 15%, supported by organic growth and acquisitions. At the same time, BRAINBioIncubator continues to offer additional upside through the commercialization of innovative biotechnology projects.
Long-Term Growth Drivers in Industrial Biotechnology
The presentation also explains how BRAIN Biotech benefits from long-term structural trends including sustainable manufacturing, biologization of industrial processes, growing demand for specialty enzymes, and increasing adoption of biological solutions across multiple industries. Management’s long-term ambition is to establish BRAIN Biotech as one of the Top 10 global enzyme companies.
▶️ Other videos:
Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/
Company Presentation: https://seat11a.com/investor-relations-company-presentation/
Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/
Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/
ESG Presentation: https://seat11a.com/investor-relations-esg/
T&C
This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.
